As Its Debut Cancer Drug Struggles, MorphoSys Continues Refocus With $1bn Licensing Deal

Two Assets Outlicensed

 
• By Andrew McConaghie
  
MorphoSys
The outlicensing deal will free up MorphoSys' internal resources to focus on key pipeline assets, starting with pelabresib. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip